文献速递骨软组织肉瘤与黑色素瘤

转移性黑色素瘤患者对免疫治疗的T细胞免疫唤醒呈年龄依赖性

T cell immune awakening in response to immunotherapy is age-dependent.
PubMed 文献 · Eur J Cancer · 2021-12-21

研究纳入50例一线接受抗PD-1免疫检查点阻断(ICB)治疗的转移性黑色素瘤患者,分析治疗前(T0)及第一周期后第3周(W3)的TCR库和外周TIE细胞动态与年龄的关系。结果发现TIE丰度与年龄在T0相关(r=0.40),W3时减弱(r=0.07);W3时缓解患者TCR库重排呈两种显著相反模式(p=0.03),≥70岁者TCR克隆性增加,<70岁者TCR多样性增加。结论认为免疫治疗诱导的免疫唤醒模式与年龄相关,可能影响ICB应答。

要点

  • 转移性黑色素瘤患者一线抗PD-1治疗,TIE丰度与年龄在治疗前相关(r=0.40),第3周减弱(r=0.07)。
  • 第3周缓解患者TCR库重排呈两种显著相反模式(p=0.03):≥70岁者克隆性增加,<70岁者多样性增加。
  • 免疫治疗诱导的免疫唤醒模式与年龄相关,可能影响ICB应答,对生物标志物开发和个体化治疗策略有启示。

核心结论

  • 免疫治疗诱导的黑色素瘤患者免疫唤醒模式与年龄相关,可能影响患者对ICB的应答,对生物标志物开发和个体化治疗策略规划有启示。

研究设计与样本

  • 纳入50例接受一线抗PD-1免疫检查点阻断(ICB)治疗的转移性黑色素瘤患者,分析治疗前(T0)和第一周期后第3周(W3)的TCR库及外周TIE细胞动态与年龄的关系。

主要发现

  • TIE丰度与年龄在T0相关(r=0.40),W3时该相关性减弱(r=0.07)。
  • W3时缓解患者TCR库重排呈两种显著相反模式(p=0.03):≥70岁患者TCR克隆性增加,<70岁患者TCR多样性增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Precision immuno-oncology approaches are needed to improve cancer care. We recently demonstrated that in patients with metastatic melanoma, an increase of clonality or diversity of the T cell receptor (TCR) repertoire of peripheral T cells following one cycle of immunotherapy is coincident with response to immune-checkpoint blockade (ICB). We also identified a subset of peripheral CD8+ immune-effector memory T cells (TIE cells) whose expansion was associated with response to ICB and increased overall survival. To improve our understanding of peripheral T cell dynamics, we examined the clinical correlates associated with these immune signatures. METHODS: Fifty patients with metastatic melanoma treated with first-line anti-PD-1 ICB were included. We analysed TCR repertoire and peripheral TIE cell dynamics by age before treatment (T0) and after the first cycle of treatment at week 3 (W3). RESULTS: We observed a correlation between TIE abundance and age at T0 (r = 0.40), which reduced following treatment at W3 (r = 0.07). However, at W3, we observed two significantly opposing patterns (p = 0.03) of TCR repertoire rearrangement in patients who responded to treatment, with patients ≥70 years of age showing an increase in TCR clonality and patients <70 years of age showing an increase in TCR diversity. CONCLUSIONS: We demonstrate that immunotherapy-induced immune-awakening patterns in patients with melanoma are age-related and may impact patient response to ICB, and thus have implications for biomarker development and planning of personalised therapeutic strategies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Salih Z, Banyard A, Tweedy J, et al. T cell immune awakening in response to immunotherapy is age-dependent. Eur J Cancer. 2021. PMID: 34952479. doi:10.1016/j.ejca.2021.11.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。